



Model List of Essential Medicines



Arsenic trioxide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)



Asparaginase [General information](#)

Section

Cytotoxic medicines

- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified](#)



Azacitidine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

[Myeloid leukaemia](#)



Bendamustine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma](#)



Bleomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

[Other specified malignant neoplasms of the ovary Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Calcium folinate (leucovorin calcium) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasm metastasis in large intestine](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant trophoblastic neoplasms of placenta](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)

Capecitabine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid > tablet: 150 mg; 500 mg

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#) [Other specified malignant neoplasms of breast](#)

Carboplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified gliomas of brain](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Other specified carcinomas of ovary](#) [Retinoblastoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of oropharynx](#)

Chlorambucil [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 2 mg tablet

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Cisplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of nasopharynx](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of oropharynx](#)

Cladribine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

[Langerhans cell histiocytosis](#)



Cyclophosphamide [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified malignant neoplasms of breast](#) [Follicular lymphoma](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of breast](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Hodgkin lymphoma](#) [Plasma cell myeloma](#) [Other specified gliomas of brain](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Lymphoid leukaemia, not elsewhere classified](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Rhabdomyosarcoma primary site](#)



Cytarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Dacarbazine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

[Hodgkin lymphoma](#)



Dactinomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

[Malignant trophoblastic neoplasms of placenta](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)



Daunorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#)



Docetaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of prostate](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)



Doxorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Rhabdomyosarcoma primary site](#) [Follicular lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Other specified malignant neoplasms of breast](#) [Hodgkin lymphoma](#) [Plasma cell myeloma](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Kaposi sarcoma of unspecified primary site](#)



Doxorubicin (as pegylated liposomal) [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Kaposi sarcoma of unspecified primary site](#)



Etoposide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Germ cell tumour of testis](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Hodgkin lymphoma](#) [Retinoblastoma](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Fludarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Fluorouracil [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
- Parenteral > General injections > IV: 50 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of rectum](#) [Malignant](#)

[neoplasms of colon](#)



Gemcitabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified carcinomas of ovary](#) [Other specified malignant neoplasms of bronchus or lung](#)



Hydroxycarbamide (hydroxyurea) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

[Squamous cell carcinoma of oropharynx](#) [Chronic myeloid leukaemia, not elsewhere classified](#)



Ifosfamide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Rhabdomyosarcoma primary site](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Irinotecan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#)



Melphalan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

[Plasma cell myeloma](#)



Mercaptopurine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 50 mg tablet
- Oral > Liquid: 20 mg per mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Langerhans cell histiocytosis](#)



Methotrexate [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Oxaliplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of colon](#)



Paclitaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

[Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of nasopharynx](#) [Kaposi sarcoma of unspecified primary site](#) [Other specified malignant neoplasms of breast](#) [Other specified carcinomas of ovary](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of cervix uteri](#)



Pegaspargase [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#)



Procarbazine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)
- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Hodgkin lymphoma](#)



Realgar-indigo naturalis formulation [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)



Temozolomide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

[Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Other specified gliomas of brain](#) [Neuroblastoma, NOS](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)



Tioguanine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 40 mg

Indications

[Lymphoid leukaemia, not elsewhere classified](#)



Vinblastine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Hodgkin lymphoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Kaposi sarcoma of unspecified primary site](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Vincristine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Follicular lymphoma](#) [Malignant trophoblastic neoplasms of placenta](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Kaposi sarcoma of unspecified primary site](#) [Rhabdomyosarcoma primary site](#) [Hodgkin lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Lymphoid leukaemia, not elsewhere classified](#) [Retinoblastoma](#) [Langerhans cell histiocytosis](#)



Vinorelbine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified malignant neoplasms of breast](#) [Rhabdomyosarcoma primary site](#)